Abstract library

965 results for "time to progression".
#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease
Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Espen Thiis-Evensen
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
#486 Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study
Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P<0.0001).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Anja Rinke
Authors: Rinke A
#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms
Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Francesco Panzuto
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#1830 Increase of the Ki67 Proliferation Index over Time in Patients with Neuroendocrine Neoplasms
Introduction: Whether the Ki67 index increases over time in relation to progression is scarcely studied.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Pernille Holmager
#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David C. Metz
Authors: Metz D C, Liu E, Joish V N, Huynh L, ...
#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J, Li Z P, Feng S T, ...
#997 Comparison of Different Diagnostic Methods for the Assessment of Progression in Patients with Neuroendocrine Tumors (NET)
Introduction: Different imaging and laboratory methods are used to evaluate patients with NET.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Florian Keplinger
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...